Phase 3 Trial Update: Recent posts on X have been buzzing with news about Annovis Bio’s progress in its Phase 3 trial for Alzheimer’s disease. Many users highlighted the activation of all 84 U.S. trial sites and the milestone of the first group of patients completing six months of treatment. There’s a sense of anticipation around potential outcomes as the trial advances.
Financial Reports: Discussions also touched on Annovis Bio’s Q3 2025 financial results, with some users noting a reported earnings miss despite a year-over-year improvement in adjusted EPS. Posts mentioned the company’s cash reserves of $15.3 million, seen as sufficient to fund operations into Q3 2026. A few expressed curiosity about how these figures might impact future trial funding.
Stock Movement: Some chatter on X focused on recent insider buying by the CEO, with a transaction worth $200,000, sparking interest among followers. There’s also mention of stock offerings and a slight price dip, with mixed reactions on what this means for investor confidence. The dialogue remains active as news continues to unfold.
Note: This discussion summary was generated from an AI condensation of post data.
Annovis Bio Insider Trading Activity
Annovis Bio insiders have traded $ANVS stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ANVS stock by insiders over the last 6 months:
- MICHAEL B HOFFMAN purchased 975,610 shares for an estimated $2,000,000
- MARIA-LUISA MACCECCHINI (President & CEO) purchased 97,561 shares for an estimated $200,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Annovis Bio Hedge Fund Activity
We have seen 19 institutional investors add shares of Annovis Bio stock to their portfolio, and 18 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TWO SIGMA INVESTMENTS, LP removed 166,219 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $360,695
- UBS GROUP AG removed 134,559 shares (-83.6%) from their portfolio in Q2 2025, for an estimated $291,993
- TWO SIGMA ADVISERS, LP removed 92,921 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $201,638
- MARSHALL WACE, LLP added 90,907 shares (+inf%) to their portfolio in Q2 2025, for an estimated $197,268
- VANGUARD GROUP INC added 41,239 shares (+5.9%) to their portfolio in Q3 2025, for an estimated $85,364
- WARBERG ASSET MANAGEMENT LLC removed 39,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $84,630
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 36,853 shares (+28.9%) to their portfolio in Q2 2025, for an estimated $79,971
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Annovis Bio Analyst Ratings
Wall Street analysts have issued reports on $ANVS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 09/30/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/03/2025
To track analyst ratings and price targets for Annovis Bio, check out Quiver Quantitative's $ANVS forecast page.
Annovis Bio Price Targets
Multiple analysts have issued price targets for $ANVS recently. We have seen 2 analysts offer price targets for $ANVS in the last 6 months, with a median target of $13.5.
Here are some recent targets:
- Sumant Kulkarni from Canaccord Genuity set a target price of $17.0 on 09/30/2025
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $10.0 on 09/03/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
